Empagliflozin ameliorates obesity-related cardiac dysfunction by regulating Sestrin2-mediated AMPK-mTOR signaling and redox homeostasis in high-fat diet-induced obese mice
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have favorable cardiovascular outcomes in patients with diabetes. However, whether SGLT2i can improve obesity-related cardiac dysfunction is unknown. Sestrin2 is a novel stress-inducible protein that regulates AMPK–mammalian target of rapamycin (mTOR) and suppresses oxidative damage. The aim of this study was to determine whether empagliflozin (EMPA) improves obesity-related cardiac dysfunction via regulating Sestrin2-mediated pathways in diet-induced obesity. C57BL/6J mice and Sestrin2 knockout mice were fed a high-fat diet (HFD) for 12 weeks and then treated with or without EMPA (10 mg/kg) for 8 weeks. Treating HFD-fed C57BL/6J mice with EMPA reduced body weight and whole-body fat and improved metabolic disorders. Furthermore, EMPA improved myocardial hypertrophy/fibrosis and cardiac function and reduced cardiac fat accumulation and mitochondrial injury. Additionally, EMPA significantly augmented Sestrin2 levels and increased AMPK and endothelial nitric oxide synthase phosphorylation, but inhibited Akt and mTOR phosphorylation. These beneficial effects were partially attenuated in HFD-fed Sestrin2 knockout mice. Intriguingly, EMPA treatment enhanced the Nrf2/HO-1–mediated oxidative stress response, suggesting antioxidant and anti-inflammatory activity. Thus, EMPA improved obesity-related cardiac dysfunction via regulating Sestrin2-mediated AMPK-mTOR signaling and maintaining redox homeostasis. These findings provide a novel mechanism for the cardiovascular protection of SGLT2i in obesity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, several antifibrotic interventions -including traditional Chinese medicinal (TCM) compounds and pharmaceutical agents such as metformin, glucagon-like peptide-1 receptor agonists (GLP-1RAs) or SGLT2 inhibitors (SGLT2is)- promote restorative macrophage polarization, at least in part, through activation of AMPK-dependent pathways and enhance hepatic autophagy (34, 39, 41–44).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [43]
Citations
Cites
p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling
Budanov, A. V., & Karin, M. (2008) · Cell · doi:10.1016/j.cell.2008.06.028 · Cited by 1,326 · cited 2×
“Sesn2 also promotes phosphorylation of AMPK through its upstream kinase liver kinase B1 (LKB1)– dependent way and mediates genotoxic stress-induced AMPK activation and mTOR inhibition (12,13).”
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease
Steven, S., Frenis, K., Oelze, M., Kalinovic, S., Kuntic, M., Bayo Jimenez, M. T., Vujacic-Mirski, K., Helmstädter, J., Kröller-Schön, S., Münzel, T., et al. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/7092151 · Cited by 708
Li, C., Zhang, J., Xue, M., Li, X., Han, F., Liu, X., Xu, L., Lu, Y., Cheng, Y., Li, T., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0816-2 · Cited by 580
Self-citationZhou, H., Wang, S., Zhu, P., Hu, S., Chen, Y., & Ren, J. (2018) · Redox Biology · doi:10.1016/j.redox.2017.12.019 · Cited by 550 · cited 1×
“We found that EMPA treatment triggered eNOS phosphorylation at Ser(1177), indicating endothelial-protective effects of EMPA, which is consistent with a previous study (42).”
Mahaffey, K. W., Neal, B., Perkovic, V., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Fabbrini, E., Sun, T., Li, Q., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032038 · Cited by 498
Bae, S. H., Sung, S. H., Oh, S. Y., Lim, J. M., Lee, S. K., Park, Y. N., Lee, H. E., Kang, D., & Rhee, S. G. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2012.12.002 · Cited by 492 · cited 1×
“(41) reported that Sesn2 induces Nrf2 activation by enhancing the autophagic degradation of Keap1.”
Wu, J. H. Y., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundström, J., & Neal, B. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00052-8 · Cited by 474
Ye, Y., Bajaj, M., Yang, H.-C., Perez-Polo, J. R., & Birnbaum, Y. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6725-2 · Cited by 368
Fitchett, D., Inzucchi, S. E., Cannon, C. P., McGuire, D. K., Scirica, B. M., Johansen, O. E., Sambevski, S., Kaspers, S., Pfarr, E., George, J. T., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037778 · Cited by 351
Cited by
Bhatti, J. S., Sehrawat, A., Mishra, J., Sidhu, I. S., Navik, U., Khullar, N., Kumar, S., Bhatti, G. K., & Reddy, P. H. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.03.019 · Cited by 693
Ketone bodies: from enemy to friend and guardian angel
Kolb, H., Kempf, K., Röhling, M., Lenzen-Schulte, M., Schloot, N. C., & Martin, S. (2021) · BMC Medicine · doi:10.1186/s12916-021-02185-0 · Cited by 361
Neuroprotective effect of SGLT2 inhibitors.
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021) · Molecules · doi:10.3390/molecules26237213 · Cited by 304
“Reduced mTOR Signaling n/a Yes [51] Yes [51] Yes [52] Yes [53]”
BackgroundAn Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Di Martino, A., Albanese, G., Di Salvo, J., Epifani, R., Marfella, R., Docimo, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073651 · Cited by 256
Winiarska, A., Knysak, M., Nabrdalik, K., Gumprecht, J., & Stompór, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910822 · Cited by 191
Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy
Byrne, N. J., Rajasekaran, N. S., Abel, E. D., & Bugger, H. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.03.046 · Cited by 174
Direct cardiac effects of SGLT2 inhibitors
Chen, S., Coronel, R., Hollmann, M. W., Weber, N. C., & Zuurbier, C. J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01480-1 · Cited by 174
Dyck, J. R. B., Sossalla, S., Hamdani, N., Coronel, R., Weber, N. C., Light, P. E., & Zuurbier, C. J. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.03.005 · Cited by 169
Metabolic liver disease in diabetes – From mechanisms to clinical trials
Dewidar, B., Kahl, S., Pafili, K., & Roden, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154299 · Cited by 158
Marino, A., Hausenloy, D. J., Andreadou, I., Horman, S., Bertrand, L., & Beauloye, C. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.02.047 · Cited by 148
Tuleta, I., & Frangogiannis, N. G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113904 · Cited by 150
Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
Tsai, K., Chen, Y., Chiou, T. T., Chu, T., Li, L., Ng, H., Lee, W., & Lee, C. (2021) · Antioxidants · doi:10.3390/antiox10081166 · Cited by 148
Penna, C. R. R., & Pagliaro, P. (2025) · Antioxidants · doi:10.3390/antiox14030256 · Cited by 164
Cardiorenal protection of SGLT2 inhibitors—Perspectives from metabolic reprogramming
Gao, Y.-M., Feng, S., Wen, Y., Tang, T., Wang, B., & Liu, B. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104215 · Cited by 131
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors
Dabour, M. S., George, M. Y., DANIEL, M. R., Blaes, A. H., & Zordoky, B. N. M. (2024) · JACC CardioOncology · doi:10.1016/j.jaccao.2024.01.007 · Cited by 136
Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
Huang, K., Luo, X., Liao, B., Li, G., & Feng, J. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01816-5 · Cited by 126
Cardiac Aging: From Basic Research to Therapeutics
Yan, M., Sun, S., Xu, K., Huang, X., Dou, L., Pang, J., Tang, W., Shen, T., & Li, J. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9570325 · Cited by 89
Self-citationGuidelines on models of diabetic heart disease
Heather, L. C., Hafstad, A. D., Halade, G. V., Harmancey, R., Mellor, K. M., Mishra, P. K., Mulvihill, E. E., Nabben, M., Nakamura, M., Rider, O. J., et al. (2022) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00058.2022 · Cited by 97
Immunomodulatory Effects of SGLT2 Inhibitors—Targeting Inflammation and Oxidative Stress in Aging
Schönberger, E., Mihaljević, V., Steiner, K., Šarić, S., Kurevija, T., Majnarić, L. T., Bilić-Čurčić, I., & Canecki-Varžić, S. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20176671 · Cited by 93
Yan, Y., Li, M., Lin, J., Ji, Y., Wang, K., Yan, D., Shen, Y., Wang, W., Huang, Z., Jiang, H., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.947387 · Cited by 89
El‐Horany, H. E., Atef, M. M., Ghafar, M. T. A., Fouda, M. H., Nasef, N. A., Hegab, I. I., Helal, D. S., Elseady, W. S., Hafez, Y. M., Hagag, R. Y., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119481 · Cited by 80
Croteau, D., Luptak, I., Chambers, J. M., Hobai, I., Panagia, M., Pimentel, D. R., Siwik, D. A., Qin, F., & Colucci, W. S. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019995 · Cited by 73
Zhang, J., He, Z., Fedorova, J., Logan, C., Bates, L., Davitt, K., Le, T. N. V., Murphy, J., Li, M., Wang, M., et al. (2021) · Aging Cell · doi:10.1111/acel.13419 · Cited by 77
Self-citationAla, M., Khoshdel, M. R. F., & Dehpour, A. R. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1197061 · Cited by 81
SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD
Ala, M. (2021) · Endocrinology · doi:10.1210/endocr/bqab157 · Cited by 75
Endothelial Dysfunction in Obesity and Therapeutic Targets
Engin, A. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-63657-8_17 · Cited by 97
Abdelhamid, A. M., Saber, S., Youssef, M. E., Gaafar, A. G. A., Eissa, H., Abdel-Dayem, M. A., Alqarni, M., Batiha, G. E., Obaidullah, A. J., Shahien, M. A., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112455 · Cited by 71
Sestrins in Physiological Stress Responses
Kim, M., Kowalsky, A. H., & Lee, J. H. (2020) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-092317 · Cited by 70
Min, J., Wu, L., Liu, Y., Song, G., Deng, Q., Wei, J. J., Yu, W., Abudureyimu, M., Pei, Z., & Ren, J. T. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121207 · Cited by 67
Lin, K.-J., Wang, T., Chen, S., Lin, K.-L., Liou, C., Lan, M., Chuang, Y., Chuang, J., Wang, P., Lee, J., et al. (2021) · Antioxidants · doi:10.3390/antiox10121935 · Cited by 65
Heather, L. C., Gopal, K., Srnic, N., & Ussher, J. R. (2024) · Diabetes · doi:10.2337/dbi23-0019 · Cited by 69
Quercetin activates the Sestrin2/AMPK/SIRT1 axis to improve amyotrophic lateral sclerosis
Jin, T., Zhang, Y., Botchway, B. O. A., Huang, M., Lu, Q., & Liu, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114515 · Cited by 64
Self-citationAntioxidant Roles of SGLT2 Inhibitors in the Kidney
Llorens-Cebrià, C., den Bosch, M. M. V., Vergara, A., Jacobs-Cachá, C., & Soler, M. J. (2022) · Biomolecules · doi:10.3390/biom12010143 · Cited by 57
Alsereidi, F. R., Khashim, Z., Marzook, H., Gupta, A., Al-Rawi, A. M., Ramadan, M. M., & Saleh, M. A. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102524 · Cited by 66
Abdelkader, N. F., Elbaset, M. A., Moustafa, P. E., & Ibrahim, S. M. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01391-5 · Cited by 56
Scisciola, L., Taktaz, F., Fontanella, R. A., Pesapane, A., Surina, Cataldo, V., Ghosh, P., Franzese, M., Puocci, A., Paolisso, P., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01754-2 · Cited by 54
Sestrin2 as a Potential Target for Regulating Metabolic-Related Diseases
Gong, L., Wang, Z., Wang, Z., & Zhang, Z. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.751020 · Cited by 58
Li, X., Flynn, E. R., do Carmo, J. M., Wang, Z., da Silva, A. A., Mouton, A. J., Omoto, A. C. M., Hall, M. E., & Hall, J. E. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.859253 · Cited by 61
Self-citationLong-Term High-Fat High-Fructose Diet Induces Type 2 Diabetes in Rats through Oxidative Stress
Zhao, Y., Wang, Q., Zeng, L.-T., Wang, J.-J., Liu, Z., Fan, G., Li, J., & Cai, J. (2022) · Nutrients · doi:10.3390/nu14112181 · Cited by 51
Self-citationSestrin 2, a potential star of antioxidant stress in cardiovascular diseases
Liu, Y., Li, M., Du, X., Huang, Z., & Quan, N. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.11.015 · Cited by 49
Wang, Y., Ding, Y., Sun, P., Zhang, W., Xin, Q., Wang, N., Niu, Y., Chen, Y., Luo, J., Lu, J., et al. (2022) · Antioxidants · doi:10.3390/antiox11050799 · Cited by 46
Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling (Review)
Chen, B., Guo, J., Ye, H., Wang, X., & Feng, Y. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13197 · Cited by 47
Abdelhamid, A. M., Youssef, M. E., El-Fattah, E. E. A., Gobba, N. A., Gaafar, A. G. A., Girgis, S., Shata, A., Abdel-Moneim, A.-M. H., El-Ahwany, E. G., Amin, N. A., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120070 · Cited by 46
Witham, M. D., Granic, A., Pearson, E. R., Robinson, S. M., & Sayer, A. A. (2023) · Drugs & Aging · doi:10.1007/s40266-023-01042-4 · Cited by 49
Myocardial Energy Metabolism in Non-ischemic Cardiomyopathy
Greenwell, A. A., Gopal, K., & Ussher, J. R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.570421 · Cited by 43
Balogh, D. B., Wagner, L. J., & Fekete, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097789 · Cited by 38
Sestrin2 as a potential therapeutic target for cardiovascular diseases
Gao, A., Li, F., Zhou, Q., & Chen, L. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104990 · Cited by 40
Lu, C.-W., Lee, C., Hsieh, Y.-J., & Hsu, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210016 · Cited by 45
Ma, Y., Zhang, G., Kuang, Z., Xu, Q., Ye, T., Li, X., Qu, N., Han, F., Kan, C., & Sun, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.944886 · Cited by 38
Self-citationBenefits of SGLT2 inhibitors in arrhythmias
Gao, J., Xue, G., Zhan, G., Wang, X., Li, J., Yang, X., & Xia, Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1011429 · Cited by 41
Self-citationQu, N., Qu, J., Huang, N., Zhang, K., Ye, T., Shi, J., Chen, B., Kan, C., Zhang, J., Han, F., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1056687 · Cited by 36
Self-citationRepurposing SGLT2 Inhibitors for Neurological Disorders: A Focus on the Autism Spectrum Disorder
Nakhal, M. M., Aburuz, S., Sadek, B. S., & Akour, A. A. (2022) · Molecules · doi:10.3390/molecules27217174 · Cited by 33
Ugwoke, C. K., Cvetko, E., & Umek, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020847 · Cited by 42
Wu, X., Huang, J., Tang, J., Sun, Y., Zhao, G., Yan, C., Liu, Z., Yi, W., Xu, S., & Yu, X. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102485 · Cited by 35
Lyu, Y.-T., Huo, J., Jiang, W., Yang, W., Yang, W., Wang, S., Cheng, Y., Jiang, Z., & Shan, Q. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175531 · Cited by 34
Wang, K., Li, Z., Sun, Y., Liu, X., Ma, W., Ding, Y., Hong, J., Qian, L., & Xu, D. (2021) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-021-10192-y · Cited by 31
Ferreira, J. P., Verma, S., FITCHETT, D. H., Ofstad, A. P., Lauer, S., Zwiener, I., George, J. T., Wanner, C., Zinman, B., & Inzucchi, S. E. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01174-6 · Cited by 33
Bian, J., Ding, Y., Wang, S., Jiang, Y., Wang, M., Wei, K., Si, L., Zhao, X., & Shao, Y. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.03.004 · Cited by 29
Xie, L., Xiao, Y., Tai, S., Yang, H., Zhou, S., & Zhou, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.836849 · Cited by 35
Bugga, P., Mohammed, S. A., Alam, M. J., Katare, P. B., Meghwani, H., Maulik, S. K., Arava, S. K., & Banerjee, S. K. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120862 · Cited by 33
Target Sestrin2 to rescue the damaged organ: mechanistic insight into its function
Ala, M., & Eftekhar, S. P. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/8790369 · Cited by 27
“Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, could mitigate obesity-induced cardiac dysfunction in mice [121].”
BackgroundInfluentialShi, J., Qiu, H., Xu, Q., Ma, Y., Ye, T., Kuang, Z., Qu, N., Kan, C., Hou, N., Han, F., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105816 · Cited by 37
Self-citationHFpEF and MASLD: converging mechanisms and clinical implications
Capone, F., Häseli, S. P., Liu, L., Strocchi, S., Langenberg, C., Lusis, A. J., Pietzner, M., Muoio, D. M., Rider, O. J., Raman, B., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01257-z · Cited by 37
mTORC1 and SGLT2 Inhibitors—A Therapeutic Perspective for Diabetic Cardiomyopathy
Saha, S., Fang, X., Green, C. D., & Das, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015078 · Cited by 26
Yang, G., Zhang, Q., Dong, C., Hou, G., Li, J., Meng, L., Jiang, X. M., & Xin, Y. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31149 · Cited by 24
Self-citationHan, F., Kan, C., Wu, D., Kuang, Z., Song, H., Luo, Y., Zhang, L., Hou, N., & Sun, X. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01727-6 · Cited by 25
Self-citationNew insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling
Chen, Y., & Peng, D. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110072 · Cited by 30
Nakhal, M. M., Jayaprakash, P., Aburuz, S., Sadek, B. S., & Akour, A. A. (2023) · Pharmaceuticals · doi:10.3390/ph16050769 · Cited by 26
Sestrin2 Signaling Pathway Regulates Podocyte Biology and Protects against Diabetic Nephropathy
Ala, M. (2023) · Journal of Diabetes Research · doi:10.1155/2023/8776878 · Cited by 25
Ma, Y., Kan, C., Qiu, H., Liu, Y., Hou, N., Han, F., Shi, J., & Sun, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.793586 · Cited by 25
Self-citationPiperis, C., Marathonitis, A., Anastasiou, A., Theofilis, P., Mourouzis, K., Giannakodimos, A., Tryfou, E. S., Oikonomou, E. K., Siasos, G., & Tousoulis, D. (2024) · Biomedicines · doi:10.3390/biomedicines12102314 · Cited by 28
Abdelhadi, N., Ragab, K. M., Elkholy, M., Koneru, J. N., Ellenbogen, K. A., & Pillai, A. (2025) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.16544 · Cited by 21
Zhou, W., Young, J. L., Men, H., Zhang, H., Yu, H., Lin, Q., Xu, H., Xu, J., Tan, Y., Zheng, Y., et al. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.152176 · Cited by 21
Insights into Concomitant Atrial Fibrillation and Chronic Kidney Disease
Wang, Y., Yang, Y., & He, F. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2303105 · Cited by 26
Mechanisms of cardio-renal protection of sodium-glucose cotransporter-2 inhibitors
Chiriacò, M., Tricò, D., & Solini, A. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102272 · Cited by 22
Zhang, L., Zhang, H., Xie, X., Tie, R., Shang, X., Zhao, Q., Xu, J., Jin, L., Zhang, J., & Ye, P. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01061-6 · Cited by 26
Self-citationThe link between obesity and aging - insights into cardiac energy metabolism
Owesny, P., & Grune, T. (2023) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111870 · Cited by 25
Papaetis, G. S. (2021) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2021.105314 · Cited by 25
A paradoxical role for sestrin 2 protein in tumor suppression and tumorigenesis
Qu, J., Luo, M., Zhang, J., Han, F., Hou, N., Pan, R., & Sun, X. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02317-9 · Cited by 22
Self-citationEmerging role of antidiabetic drugs in cardiorenal protection
Fu, W.-J., Huo, J., Mao, Z., Pan, S.-K., Liu, D., Liu, Z., Wu, P., & Gao, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1349069 · Cited by 24
Yang, C., Chen, K.-H., Yue, Y., Cheng, B., Hsu, T., Chiang, J. Y., Chen, C., Liu, F., Xiao, J., & Yip, H.-K. (2024) · Journal of Molecular Histology · doi:10.1007/s10735-024-10233-1 · Cited by 21
Sestrin2 as a Protective Shield against Cardiovascular Disease
Zahid, M., Abdelsalam, S. S., Raïq, H., Parray, A., Korashy, H. M., Zeidan, A., Elrayess, M. A., & Agouni, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054880 · Cited by 23
Ma, Y., Xu, M., Cen, X.-F., Qiu, H.-L., Guo, Y., & Tang, Q. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116589 · Cited by 19
Gong, S., Sui, Y., Xiao, M., Fu, D., Xiong, Z., Zhang, L., Tian, Q., Fu, Y., & Xiong, W. (2024) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001625 · Cited by 20
Zhou, R., Zhang, Z., Li, X., Duan, Q., Miao, Y., Zhang, T., Wang, M., Li, J., Zhang, W., Wang, L., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041668 · Cited by 21
Self-citationIshikane, S., Arioka, M., & Takahashi‐Yanaga, F. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115663 · Cited by 19
Lei, L., Zhu, T., Cui, T.-J., Liu, Y., Hocher, J.-G., Chen, X., Zhang, X.-M., Cai, K., Deng, Z.-Y., Wang, X., et al. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00367.2024 · Cited by 18
Li, K., Sun, J., Huang, N., Ma, Y., Han, F., Liu, Y., Hou, N., & Sun, X. (2020) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13391 · Cited by 18
Self-citationAn assessment of thermoneutral housing conditions on murine cardiometabolic function
Chen, X., Bollinger, E., Cunio, T., Damilano, F., Stansfield, J. C., Pinkus, C. A., Kreuser, S. C., Hirenallur-Shanthappa, D. K., & Flach, R. J. R. (2021) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00461.2021 · Cited by 18
Noh, H., Joo, S. Y., Kim, C. H., Choi, S.-W., Lee, C. H., & Hwang, J. K. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02389-3 · Cited by 17
Mitophagy Disequilibrium, a Prominent Pathological Mechanism in Metabolic Heart Diseases
Li, Y., Zheng, N., & Ding, X. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s336882 · Cited by 18
Anti-diabetic drug canagliflozin hinders skeletal muscle regeneration in mice
Lv, X., Cong, X., Nan, J., Lu, X.-M., Zhu, Q., Shen, J., Wang, B., Wang, Z., Zhou, R., Chen, W., et al. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00878-7 · Cited by 17
Effect of high-fat diet and empagliflozin on cardiac proteins in mice
Pan, X., Chen, S., Chen, X., Ren, Q., Yue, L., Niu, S., Li, Z., Zhu, R., Chen, X., Jia, Z., et al. (2022) · Nutrition & Metabolism · doi:10.1186/s12986-022-00705-0 · Cited by 16
Metabolomics Provides Insights into Renoprotective Effects of Semaglutide in Obese Mice
Chen, X., Chen, S., Ren, Q., Niu, S., Pan, X., Yue, L., Li, Z., Zhu, R., Jia, Z., Chen, X., et al. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s383537 · Cited by 17
Acetyl-CoA carboxylase activation disrupts iron homeostasis to drive ferroptosis
Han, Z., Han, S., Fang, X., Lu, M., Mao, Y., Shi, L., Song, J., Wang, T., Xiao, J., Xiang, L., et al. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.05.421 · Cited by 15
Lee, S., Chung, K., Son, S.-R., Lee, S. Y., Jang, D. S., Lee, J.-K., Kim, H., Na, C., Lee, S.-H., & Lee, K. (2022) · Nutrients · doi:10.3390/nu14183685 · Cited by 14
Azizian, H., Farhadi, Z., Bäder, M., Ghalenoei, J. A., Ghafari, M. A., & Mahmoodzadeh, S. (2023) · PLoS ONE · doi:10.1371/journal.pone.0293630 · Cited by 16
Luo, Y., Ye, T., Tian, H., Song, H., Kan, C., Han, F., Hou, N., Sun, X., & Zhang, J. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02293-9 · Cited by 14
Self-citationDapagliflozin Alleviates High-Fat-Induced Obesity Cardiomyopathy by Inhibiting Ferroptosis
Chen, D., Shi, J., Wu, Y., Miao, L., Wang, Z., Wang, Y., Xu, S., & Lou, Y. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15150 · Cited by 16
Li, Q., Cao, Q., Yuan, Z., Wang, M., Chen, P., & Wu, X. (2022) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2022.102534 · Cited by 16
Metadata
- Authors
- Sun, X., Han, F., Lu, Q., Li, X., Ren, D., Zhang, J., Han, Y., Xiang, Y. K., & Li, J.
- Affiliations
- Weifang Medical University (CN)
- Department of Physiology and Biophysics, Mississippi Center for Heart Research, University of Mississippi Medical Center, Jackson, MS
- University of Mississippi Medical Center (US)
- University of South Florida (US)
- University of California, Davis (US)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2020-03-31
- Volume
- 69
- Issue
- 6
- Pages
- 1292-1305
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W3014209855
- Cited by
- 193
- References
- 46
- Citations by year
- 2026: 20 · 2025: 19 · 2024: 39 · 2023: 36 · 2022: 43 · 2021: 29 · 2020: 7
- FWCI
- 17.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association (1-17-IBS-296)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- empagliflozin, SGLT2 inhibitors, obesity, cardiac dysfunction, Sestrin2, AMPK/mTOR signaling, redox homeostasis, oxidative stress, Nrf2/HO-1 pathway, endothelial nitric oxide synthase, cardiac hypertrophy, myocardial fibrosis, mitochondrial injury, high-fat diet, cardioprotection
- MeSH terms
- Sestrins, Adenylate Kinase, Animals, Benzhydryl Compounds, Dietary Fats, Gene Expression Regulation, Glucosides, Heart Diseases, Homeostasis, Obesity, Oxidation-Reduction, Peroxidases, Signal Transduction, Mice, TOR Serine-Threonine Kinases, Diet, High-Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.